Aliases & Classifications for Dementia

Aliases & Descriptions for Dementia:

Name: Dementia 12 51 29 52 41 3 14 69
Presenile Dementia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1307
ICD9CM 35 290.8
UMLS 69 C0154319

Summaries for Dementia

NINDS : 51 Dementia is not a specific disease. It is a descriptive term for a collection of symptoms that can be caused by a number of disorders that affect the brain. People with dementia have significantly impaired intellectual functioning that interferes with normal activities and relationships. They also lose their ability to solve problems and maintain emotional control, and they may experience personality changes and behavioral problems, such as agitation, delusions, and hallucinations. While memory loss is a common symptom of dementia, memory loss by itself does not mean that a person has dementia. Doctors diagnose dementia only if two or more brain functions - such as memory and language skills -- are significantly impaired without loss of consciousness.  Some of the diseases that can cause symptoms of dementia are Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia, Huntington’s disease, and Creutzfeldt-Jakob disease.  Doctors have identified other conditions that can cause dementia or dementia-like symptoms including reactions to medications, metabolic problems and endocrine abnormalities, nutritional deficiencies, infections, poisoning, brain tumors, anoxia or hypoxia (conditions in which the brain’s oxygen supply is either reduced or cut off entirely), and heart and lung problems.  Although it is common in very elderly individuals, dementia is not a normal part of the aging process.

MalaCards based summary : Dementia, also known as presenile dementia, is related to juvenile amyotrophic lateral sclerosis with dementia and prion disease with protracted course, and has symptoms including angina pectoris, back pain and headache. An important gene associated with Dementia is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Neuroscience and A-beta Signaling Pathways. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior.

MedlinePlus : 41 dementia is the name for a group of symptoms caused by disorders that affect the brain. it is not a specific disease. people with dementia may not be able to think well enough to do normal activities, such as getting dressed or eating. they may lose their ability to solve problems or control their emotions. their personalities may change. they may become agitated or see things that are not there. memory loss is a common symptom of dementia. however, memory loss by itself does not mean you have dementia. people with dementia have serious problems with two or more brain functions, such as memory and language. although dementia is common in very elderly people, it is not part of normal aging. many different diseases can cause dementia, including alzheimer's disease and stroke. drugs are available to treat some of these diseases. while these drugs cannot cure dementia or repair brain damage, they may improve symptoms or slow down the disease. nih: national institute of neurological disorders and stroke

CDC : 3 The role of public health in enhancing the physical health of older adults is well-known. Public health’s role in maintaining cognitive health, a vital part of healthy aging and quality of life, is emerging. The need for a clearly delineated public health role comes at a critical time given the dramatic aging of the U.S. population, scientific advancements in knowledge about risk behaviors (e.g., lack of physical activity, uncontrolled high blood pressure) related to cognitive decline, and the growing awareness of the significant health, social, and economic burdens associated with cognitive decline. The Healthy Brain Initiative is a multifaceted approach to cognitive health with several components, including:

Wikipedia : 71 Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the... more...

Related Diseases for Dementia

Diseases related to Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 571)
id Related Disease Score Top Affiliating Genes
1 juvenile amyotrophic lateral sclerosis with dementia 33.3 APP MAPT SNCA
2 prion disease with protracted course 31.3 APOE MAPT PRNP
3 personality disorder 29.6 APOE BDNF GRN MAPT PSEN1 SNCA
4 dementia, frontotemporal 12.3
5 vascular dementia 12.3
6 dementia, lewy body 12.3
7 amyotrophic lateral sclerosis-parkinsonism/dementia complex 12.2
8 semantic dementia 12.1
9 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 12.1
10 dementia pugilistica 12.1
11 grn-related frontotemporal dementia 12.1
12 dementia, familial, nonspecific 12.1
13 inclusion body myopathy with paget disease of bone and frontotemporal dementia 12.0
14 dementia, familial danish 12.0
15 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 12.0
16 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 12.0
17 dementia - subcortical 12.0
18 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1 12.0
19 amyotrophic lateral sclerosis 14, with or without frontotemporal dementia 12.0
20 alzheimer disease 12.0
21 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 12.0
22 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 12.0
23 frontotemporal dementia with parkinsonism-17 11.9
24 amyotrophic lateral sclerosis 15, with or without frontotemporal dementia 11.9
25 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 2 11.9
26 inclusion body myopathy wtih early-onset paget disease without frontotemporal dementia 3 11.9
27 amyotrophic lateral sclerosis 22 with or without frontotemoral dementia 11.9
28 aids dementia complex 11.9
29 amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 11.9
30 dementia, familial british 11.8
31 binswanger's disease 11.8
32 pick disease 11.8
33 dnmt1-related dementia, deafness, and sensory neuropathy 11.8
34 c9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia 11.8
35 cadasil 11.8
36 behavioral variant of frontotemporal dementia 11.8
37 chorea and dementia 11.7
38 presenile dementia, kraepelin type 11.7
39 tardbp-related frontotemporal dementia 11.6
40 ubqln2-related amyotrophic lateral sclerosis/frontotemporal dementia 11.6
41 vcp-related amyotrophic lateral sclerosis/frontotemporal dementia 11.6
42 parkinsonism with dementia of guadeloupe 11.6
43 dementia with epilepsy, mapt-related 11.6
44 frontotemporal dementia, right temporal atrophy variant 11.6
45 prkar1b-related neurodegenerative dementia with intermediate filaments 11.6
46 frontotemporal lobar degeneration with ubiquitin-positive inclusions 11.6
47 nasu-hakola disease 11.5
48 supranuclear palsy, progressive atypical 11.5
49 creutzfeldt-jakob disease 11.5
50 neuropathy, hereditary sensory, type ie 11.4

Graphical network of the top 20 diseases related to Dementia:



Diseases related to Dementia

Symptoms & Phenotypes for Dementia

UMLS symptoms related to Dementia:


angina pectoris, back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

MGI Mouse Phenotypes related to Dementia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 ACHE APOE APP BDNF C9orf72 GRN
2 growth/size/body region MP:0005378 10.41 ACHE APOE APP BDNF C9orf72 MAPT
3 cellular MP:0005384 10.39 PRNP PSEN1 SNCA SQSTM1 TARDBP TYROBP
4 homeostasis/metabolism MP:0005376 10.39 ACHE APOE APP BDNF C9orf72 GRN
5 nervous system MP:0003631 10.36 PSEN1 SNCA SNCB SQSTM1 TARDBP TYROBP
6 hematopoietic system MP:0005397 10.34 PRNP PSEN1 SQSTM1 TARDBP TYROBP VCP
7 mortality/aging MP:0010768 10.33 ACHE APOE APP BDNF C9orf72 GRN
8 immune system MP:0005387 10.31 SNCA SQSTM1 TARDBP TYROBP VCP APOE
9 integument MP:0010771 10.18 APOE APP BDNF MAPT NOTCH3 PRNP
10 no phenotypic analysis MP:0003012 10.15 GRN ITM2B MAPT PRNP SNCA SNCB
11 muscle MP:0005369 10.09 APOE APP MAPT NOTCH3 PRNP PSEN1
12 reproductive system MP:0005389 9.96 ACHE APOE APP BDNF GRN NOTCH3
13 normal MP:0002873 9.92 APP BDNF MAPT NOTCH3 PRNP PSEN1
14 skeleton MP:0005390 9.9 TYROBP VCP APOE C9orf72 NOTCH3 PRNP
15 taste/olfaction MP:0005394 9.26 APOE BDNF MAPT SNCA
16 vision/eye MP:0005391 9.23 PRNP PSEN1 ACHE APOE BDNF GRN

Drugs & Therapeutics for Dementia

Drugs for Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 811)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
3
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1 59-92-7 6047
4
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
5
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
6
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1 357-70-0 9651 908828, 9651
7
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
8
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
9
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
10
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123441-03-2 77991
11
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757 53477783
12
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
13
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
14
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2216-51-5 16666
15
Nimodipine Approved Phase 4,Phase 1 66085-59-4 4497
16
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
17
Cilostazol Approved Phase 4,Phase 2 73963-72-1 2754
18
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 93-14-1 3516
19
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
20
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2 112111-43-0
21
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2 68693-11-8 4236
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Dextromethorphan Approved Phase 4,Phase 3,Phase 1,Phase 2 125-71-3 5360696 5362449
24
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
25
Nicotine Approved Phase 4,Phase 2,Phase 1 54-11-5 942 89594
26
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
27
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
28
Isoflurane Approved, Vet_approved Phase 4,Phase 1 26675-46-7 3763
29
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 99-66-1 3121
30
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
31
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
32
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
33
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 61869-08-7 43815
34
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1 79617-96-2 68617
35
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 52485-79-7 40400 644073
36
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
37
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
38
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
39
Nicergoline Approved Phase 4,Phase 3 27848-84-6 34040
40 Piracetam Approved Phase 4,Phase 3,Phase 2 7491-74-9
41
Quinidine Approved Phase 4,Phase 3,Phase 2 56-54-2 441074
42
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
43
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
44
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
45
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3 154598-52-4 64139
46
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 134678-17-4 60825
47
Nevirapine Approved Phase 4,Phase 2,Phase 3 129618-40-2 4463
48
Tenofovir Approved, Investigational Phase 4,Phase 2,Phase 3 147127-20-6 464205
49
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
50
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878

Interventional clinical trials:

(show top 50) (show all 2692)
id Name Status NCT ID Phase
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4
2 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4
3 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4
4 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4
5 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4
6 CALM-AD Unknown status NCT00142324 Phase 4
7 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
8 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4
9 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4
10 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4
11 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4
12 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4
13 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4
14 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
15 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4
16 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
17 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
18 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
19 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4
20 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4
21 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4
22 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4
23 Cilostazol Augmentation Study in Dementia Completed NCT01409564 Phase 4
24 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4
25 A Study on Behavioral and Psychological Symptoms of Dementia Completed NCT00641459 Phase 4
26 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4
27 Dementia Antipsychotics And Antidepressants Discontinuation Study Completed NCT00594269 Phase 4
28 Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? Completed NCT00164970 Phase 4
29 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed NCT01585272 Phase 4
30 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4
31 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4
32 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4
33 Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia Completed NCT00450047 Phase 4
34 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4
35 Effect of Melatonin on Sleep Quality in Patients Dementia Completed NCT03066518 Phase 4
36 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4
37 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed NCT00495820 Phase 4
38 Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18 Completed NCT02553928 Phase 4
39 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4
40 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4
41 Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD Completed NCT00433121 Phase 4
42 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4
43 Prospective Research in Memory Clinics (PRIME) Completed NCT00297271 Phase 4
44 A Comparison of Two Standard Therapies in the Management of Dementia With Agitation Completed NCT00208819 Phase 4
45 Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease Completed NCT00283725 Phase 4
46 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4
47 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4
48 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4
49 Donepezil to Treat Dementia in Parkinson's Disease Completed NCT00030979 Phase 4
50 The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia. Completed NCT00165711 Phase 4

Search NIH Clinical Center for Dementia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Dementia

Genetic tests related to Dementia:

id Genetic test Affiliating Genes
1 Dementia 29

Anatomical Context for Dementia

MalaCards organs/tissues related to Dementia:

39
Brain, Testes, Cortex, Heart, Bone, Temporal Lobe, Lung

Publications for Dementia

Articles related to Dementia:

(show top 50) (show all 4945)
id Title Authors Year
1
Dementia in Parkinson's disease. ( 28088312 )
2017
2
Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( 27901381 )
2017
3
C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. ( 28334866 )
2017
4
Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature. ( 27943639 )
2017
5
Editorial: Molecular Imaging in Dementia: From the State of the Art to the New Perspectives. ( 28088899 )
2017
6
High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK Study. ( 28039523 )
2017
7
Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies. ( 28088928 )
2017
8
Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. ( 28086755 )
2017
9
Health Services Utilization in Older Adults with Dementia Receiving CareA Coordination: The MIND at Home Trial. ( 28083879 )
2017
10
Experiences of healthcare assistants working with clients with dementia in residential care homes. ( 28084807 )
2017
11
Association of dietary cholesterol and egg intakes with the risk of incident dementia or Alzheimer disease: the Kuopio Ischaemic Heart Disease Risk Factor Study. ( 28052883 )
2017
12
Synaptic Plasticity, Dementia and Alzheimer Disease. ( 28088900 )
2017
13
Corrigendum: Dementia-associated mortality and its predictors among older adults in sub-Saharan Africa: results from a 2-year follow-up in Congo (the EPIDEMCA-FU study). ( 28087559 )
2017
14
Prevention of hypertension-induced vascular dementia by Lactobacillus paracasei subsp. paracasei NTU 101-fermented products. ( 27937042 )
2017
15
Proxy rated quality of life of care home residents with dementia: a systematic review. ( 28088926 )
2017
16
White matter damage and glymphatic dysfunction in a model of vascular dementia in rats with no prior vascular pathologies. ( 27940353 )
2017
17
An autopsy case of dementia with Lewy bodies clinically diagnosed to have a behavioral variant of frontotemporal dementia. ( 27737532 )
2017
18
Perirhinal accumulation of neuronal alpha-synuclein in a multiple system atrophy patient with dementia. ( 28419566 )
2017
19
Rapidly progressive dementia with myoclonus: Not Creutzfeldt-Jakob disease. ( 28290426 )
2017
20
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia. ( 28453471 )
2017
21
Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID). ( 27890830 )
2017
22
Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage. ( 28318355 )
2017
23
Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. ( 28074678 )
2017
24
Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. ( 28088537 )
2017
25
Association Between Exercise Capacity and Late Onset of Dementia, Alzheimer Disease, and Cognitive Impairment. ( 28082018 )
2017
26
Environmental Enrichment Improves Spatial Learning and Memory in Vascular Dementia Rats with Activation of Wnt/I^-Catenin Signal Pathway. ( 28082734 )
2017
27
ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia. ( 28088604 )
2017
28
Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia. ( 27864280 )
2017
29
Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia. ( 27845241 )
2017
30
DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies. ( 27685250 )
2017
31
Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. ( 28087719 )
2017
32
Famous faces and voices: Differential profiles in early right and left semantic dementia and in Alzheimer's disease. ( 27916672 )
2017
33
Marital Status and Persons With Dementia in Assisted Living. ( 28084096 )
2017
34
Environment as therapy: neuroscience for intellectual disability and dementia. ( 28086230 )
2017
35
Diverging Progression of Network Disruption and Atrophy in Alzheimer's Disease and Semantic Dementia. ( 27802229 )
2017
36
Frontal lobe dementia syndrome as a first manifestation of primary angiitis of the central nervous system (PACNS). ( 26773697 )
2016
37
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. ( 26938614 )
2016
38
Dementia training programmes for staff working in general hospital settings - a systematic review of the literature. ( 27662075 )
2016
39
Neuroprotective Effects of Nicorandil in Chronic Cerebral Hypoperfusion-Induced Vascular Dementia. ( 27622862 )
2016
40
Anosognosia in Dementia. ( 27438597 )
2016
41
Brain biopsy in atypical dementia and primary angiitis of the central nervous system-reply. ( 26980043 )
2016
42
Endogenous Polysialic Acid Based Micelles for Calmodulin Antagonist Delivery against Vascular Dementia. ( 27750011 )
2016
43
Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. ( 27966748 )
2016
44
Dementia strategy has not cut antipsychotic prescribing in care homes, study finds. ( 27664000 )
2016
45
Multi-infarct dementia and Alzheimer disease, contribution of cerebral circulation ultrasonography to pathogenesis and differential diagnosis. Value of microembolisation. ( 27179577 )
2016
46
Mechanisms of acupuncture on vascular dementia-A review of animal studies. ( 28034725 )
2016
47
A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. ( 27430267 )
2016
48
Effects of In-vitro Cultured Calculus Bovis on Learning and Memory Impairments of Hyperlipemia Vascular Dementia Rats. ( 27616028 )
2016
49
Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. ( 27806707 )
2016
50
Letter to the Editor: Dural arteriovenous fistula: a clinical model of thalamic dementia? ( 28009241 )
2016